Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

Alumis Inc. ( ($ALMS) ) just unveiled an announcement. On January 6, 2026, Alumis reported positive topline Phase 3 results from its ONWARD1 and ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Psoriasis is a chronic, recurrent, and incurable autoimmune disease in which the body mistakenly attacks its own tissue, ...

Oruka analysis: ultra-durable psoriasis biologics ORKA-001/002 aim for 1–3 doses/yr with strong efficacy; liquid balance ...

Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis. The stock rose 8.9% to $9.05 in after-hours trading ...

Nimbus Therapeutics has partnered with Eli Lilly in a multi-year agreement to develop AI-driven oral treatments for metabolic diseases. The deal, including potential payments of $1.3 billion, aims to ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

Jan 6 () - Nimbus Therapeutics said on Tuesday it has entered into a multi-year research and licensing agreement ​with Eli ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed ...